Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Effects of Propofol and Isoflurane on Pulmonary Vascular Resistance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01212523
Recruitment Status : Completed
First Posted : September 30, 2010
Last Update Posted : December 15, 2011
Information provided by (Responsible Party):
Michelle White, University Hospitals Bristol NHS Foundation Trust

Brief Summary:
The investigators hypothesize that there is no difference between the effects of isoflurane and propofol anaesthesia on pulmonary vascular resistance (PVR).

Condition or disease Intervention/treatment Phase
Hypertension, Pulmonary Drug: propofol and isoflurane Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Diagnostic
Official Title: Randomised Cross-over Pilot Study to Determine the Effects of Isoflurane and Propofol on Pulmonary Vascular Resistance in Children With Pulmonary Hypertension.
Study Start Date : November 2009
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

Intervention Details:
  • Drug: propofol and isoflurane
    both drugs administered at age-related dose and titrated to effect. maximum dose of propofol 15 mg/kg/hr, maximum dose of isoflurane 1.5 MAC

Primary Outcome Measures :
  1. The primary endpoint is the percentage change in PVR under isoflurane anaesthesia compared with propofol anaesthesia. [ Time Frame: 2 hours ]

Secondary Outcome Measures :
  1. The secondary endpoints are the percentage change in mean pulomanry artery pressure (PAP), systemic vascular resistance (SVR) and mean arterial pressure (MAP). [ Time Frame: 2 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   3 Months to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All children between 3 months and 16 years of age with pulmonary arterial hypertension undergoing a PVR study.

Exclusion Criteria:

  • Children with a known adverse reaction to one of the study drugs eg malignant hyperpyrexia or a disorder of fatty acid oxidation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01212523

Layout table for location information
United Kingdom
UH bristol NHS Trust
Bristol, United Kingdom, BS2 8BJ
Sponsors and Collaborators
University Hospitals Bristol NHS Foundation Trust

Layout table for additonal information
Responsible Party: Michelle White, Consultant in Paediatric Anaesthesia and Critical Care, University Hospitals Bristol NHS Foundation Trust Identifier: NCT01212523    
Other Study ID Numbers: CH/2007/2476
2009-010614-30 ( Registry Identifier: EudraCT )
First Posted: September 30, 2010    Key Record Dates
Last Update Posted: December 15, 2011
Last Verified: December 2011
Keywords provided by Michelle White, University Hospitals Bristol NHS Foundation Trust:
pulmonary hypertension
congenital heart disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anesthetics, Intravenous
Anesthetics, General
Anesthetics, Inhalation